NCT02710149

A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies

Study Summary

The main purpose of this study is to explore the therapeutic effect of CD20-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of B cell malignancies.

Want to learn more about this trial?

Request More Info

Interventions

Anti-CD20-CAR-transduced T cellsBIOLOGICAL
Patients receive autologous-derived CD20-targeted CAR-T cells on day 1, 2 after receiving lymphodepleting chemotherapy.

Study Locations

FacilityCityStateCountry
Southwest Hospital of Third Millitary Medical UniversityChongqingChongqing MunicipalityChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026